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PTEN is a lipid and protein phosphatase that regulates a diverse range of cellular
mechanisms. PTEN is mainly present in the cytosol and transiently associates with the
plasma membrane to dephosphorylate PI(3,4,5)P3, thereby antagonizing the PI3-Kinase
signaling pathway. Recently, PTEN has been shown to associate also with organelles
such as the endoplasmic reticulum (ER), the mitochondria, or the nucleus, and to
be secreted outside of the cell. In addition, PTEN dynamically localizes to specialized
sub-cellular compartments such as the neuronal growth cone or dendritic spines. The
diverse localizations of PTEN imply a tight temporal and spatial regulation, orchestrated by
mechanisms such as posttranslational modifications, formation of distinct protein–protein
interactions, or the activation/recruitment of PTEN downstream of external cues. The
regulation of PTEN function is thus not only important at the enzymatic activity level,
but is also associated to its spatial distribution. In this review we will summarize (i)
recent findings that highlight mechanisms controlling PTEN movement and sub-cellular
localization, and (ii) current understanding of how PTEN localization is achieved by
mechanisms controlling posttranslational modification, by association with binding
partners and by PTEN structural or activity requirements. Finally, we will discuss the
possible roles of compartmentalized PTEN in developing and mature neurons in health
and disease.
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INTRODUCTION
Phosphatase and tensin homolog located on chromosome 10
(PTEN) was originally characterized as a tumor suppressor that
can inhibit proliferation, migration, cell growth, and apoptosis in
a number of different cells. Subsequently it became apparent that,
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in addition to its role as a tumor suppressor, PTEN has many roles
in the central nervous system (CNS) during the different stages of
brain development and in adulthood. PTEN is highly expressed
in neurons (Lachyankar et al., 2000; Chadborn et al., 2006) and
recent work indicates that de-regulation of PTEN affects impor-
tant neuronal functions in the nervous system, which have been
attributed to its role in controlling neurogenesis, neurite out-
growth, synaptogenesis, and synaptic plasticity (Van Diepen and
Eickholt, 2008; Zhou and Parada, 2012). Human germline PTEN
mutations or conditional deletions of PTEN in mice have pro-
vided insights into possible causes associated with neurological
disorders such as macrocephaly, ataxia, seizures, mental retarda-
tion, and autism (Backman et al., 2001; Kwon et al., 2006; Van
Diepen and Eickholt, 2008; Zhou and Parada, 2012). Also, inhi-
bition of PTEN activity is currently seen as a persuasive target for
increasing regenerative capacities of neurons affected in degener-
ative conditions, or following injury to the nervous system (Park
et al., 2008).
PTEN, A PHOSPHOINOSITIDE 3-PHOSPHATASE THAT REGULATES PI3K
(PHOSPHOINOSITIDE 3 KINASE) SIGNALING
PTEN functions predominately by directly antagonizing the activ-
ity of PI3K class I heterodimeric enzymes at the plasma mem-
brane (Figure 1A). Class I PI3Ks are activated by a broad array
of growth factors, components of the extracellular matrix, and G-
protein coupled receptor (GPCR) agonists (Hawkins et al., 2006;
Frontiers in Molecular Neuroscience www.frontiersin.org April 2014 | Volume 7 | Article 23 | 1
MOLECULAR NEUROSCIENCE
Kreis et al. Dynamic regulation of PTEN in the nervous system
FIGURE 1 | PI3K signaling, PTEN, and downstream effector pathways.
(A) One of the most prominent PIP3 effectors is the protein kinase Akt.
Upon PI3K activation, Akt translocates from the cytosol to the membrane,
where it binds PIP3 and is phosphorylated and activated by PDK1
(phosphoinositide-dependent kinase 1) and the rapamycin-insensitive
complex containing mTOR (mammalian target of rapamycin), mTORC2. Akt
is considered as a master regulator of cell growth and proliferation, as well
as survival, by phosphorylating and regulating the activity of several
proteins, which convey growth-factor-derived signals to cellular functions.
For example, Akt phosphorylates and inactivates TSC2 (Tuberous Sclerosis
Complex 2), which, in a complex with TSC1, is responsible for inhibition of
RHEB (Ras Homolog Enriched in Brain). Thus, release of this inhibition
results in activation of mTORC1 complex, which is important for promoting
protein translation and accelerating cell growth in neurons. Its deregulation
is associated with several neurodevelopmental disorders (Costa-Mattioli and
Monteggia, 2013). Akt also phosphorylates and inactivates GSK3 (glycogen
synthase kinase 3), a serine/threonine kinase that has been associated with
a number of neuronal responses, particularly during neuronal development
by regulating microtubule dynamics (Hur and Zhou, 2010). Besides Akt,
PIP3 also provide a signal for membrane recruitment and activation of a
number of small GTPase regulators, particularly GEFs (Guanine nucleotide
Exchange Factors) and GAPs (GTPase Activating Proteins) of the Rho and
Arf families of GTPases (Krugmann et al., 2002; Welch et al., 2002). In this
manner PI3K, can regulate the activation state of Rho and Arf family
GTPases, thereby influencing cytoskeletal and vesicular trafficking events at
the membrane crucial for almost all aspects of neuronal polarity including
migration, neurite outgrowth as well as axon and dendrite specifications.
PTEN inhibits the signaling output of PI3Ks by dephosphorylating PIP3
back to PIP2 (PI(4,5)P2). The numerous modes of activation of PI3K by
upstream signals and growth factors are not depicted. (B) PTEN is formed
of 403 amino acids and its structure displays an N-terminal PIP2 binding
motif (PBM), a phosphatase domain, a calcium-independent lipid-binding
C2 domain, and a flexible C-terminal tail (Cter-tail) followed by a
PDZ-binding motif (PDZ) (Lee et al., 1999; Shi et al., 2012; Song et al.,
2012). The phosphatase and C2 domains form a minimal structural unit
that is capable of dephosphorylating PIP3 (Lee et al., 1999). Interestingly,
highly unstructured elements such as the PBM, parts of the C2 domain
and the C-terminal tail have important implications for the regulation of
PTEN (Lee et al., 1999; Malaney et al., 2013). The phosphatase domain
bears the P-loop signature motif of dual-specificity tyrosine phosphatases
(123HCXXGXXR130) with Cys124 being the active site residue. Mutation of
Cys124 to Ser renders PTEN inactive and this form of PTEN has been
important to determine whether PTEN functions depend on its
phosphatase activity (Myers et al., 1998). Interestingly, PTEN can also
function as a protein phosphatase and putative protein substrates have
been proposed in seminal studies (e.g., Tamura et al., 1998). The PTEN
protein phosphatase activity can be equally important for autoregulation of
PTEN and some PTEN functions pertinent to its tumor suppressive role, at
least under certain settings (Tibarewal et al., 2012; Bassi et al., 2013). The
positions of PTEN posttranslational modifications (ubiquitination and
phosphorylation) as well as catalytic and membrane binding features
(P-loop and CBR3-loop) that are discussed in the text are indicated.
Vanhaesebroeck et al., 2010). PI3Ks synthesize phosphatidyli-
nositol 3,4,5-trisphosphate (PIP3) from phosphatidylinositol 4,5-
bisphosphate (PIP2), a phosphoinositide that is particularly
enriched in the inner leaflet of the plasma membrane of all mam-
malian cells. In fact, it can be argued that this paradigm of extra-
cellular signal/agonist-induced activation of PI3Ks represents
perhaps the most prevalent signal transduction event associated
with mammalian cell-surface receptor activation (Hawkins et al.,
2006). Details concerning historical perspectives, mechanisms of
activation, feedback regulatory mechanisms and crosstalk with
other signaling modules, isoform-specific roles and downstream
effectors of this prominent signaling pathway can be found in
recent excellent reviews (Hawkins et al., 2006; Vanhaesebroeck
et al., 2010, 2012). For the purpose of this review we will only
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highlight certain aspects of PI3K signaling that are key to under-
stand the implications of PTEN function, particularly in neuronal
cells.
BASIC PRINCIPLES OF PI3K SIGNALING
Themajor and primary output of PI3K signaling is PIP3. Its rapid
synthesis upon PI3K activation coordinates the localization and
function of multiple effector proteins, which utilize specific lipid-
binding domains, such as PH (pleckstrin homology) domains,
to recognize and bind this lipid on the plasma membrane. As
suited for a second messenger, PIP3 is also subject to tight regu-
lation by specific phosphoinositide phosphatases. PTEN is one of
the most important phosphatases because it directly antagonizes
the PI3K reaction by its 3-phosphatase activity and dephospho-
rylates PIP3 back to PIP2. In this sense, PTEN represents a brake
built into PI3K signaling and its absence or dysfunction results
in the constitutive and unregulated elevation of the signaling out-
put of PI3Ks. Alternatively, PIP3 can be dephosphorylated by type
II phosphoinositide 5-phosphatases like SH2-domain contain-
ing inositol 5-phosphatases 1 and 2 (SHIP1 and SHIP2) (Leslie
et al., 2008). These enzymes generate PI3,4P2 (phosphatidyli-
nositol 3,4-bisphosphate), which can be viewed as a secondary
signaling output of PI3K. PI3,4P2 binds to sets of effector pro-
teins that overlap with PIP3 effectors but also recruits others
specifically (Vanhaesebroeck et al., 2010). Prominent PIP3 effec-
tors and the pathways that relay PI3K signaling, as well as the
domain structure of PTEN are briefly presented in the legend of
Figure 1.
BASIC PRINCIPLES OF PTEN REGULATION
PTEN expression and activity is tightly regulated at almost all
possible levels: transcriptionally, translationally, and posttrans-
lationally (Shi et al., 2012; Song et al., 2012). Perhaps the most
relevant mode of PTEN regulation, however, is through post-
translational modifications and interaction with other proteins.
PTEN is modified by phosphorylation, acetylation, oxidation, S-
nitrosylation, ubiquitination, and sumoylation (Shi et al., 2012;
Song et al., 2012; Bassi et al., 2013). A significant body of
evidence now suggests that these posttranslational modifica-
tions may influence the phosphatase activity, the binding to
the membrane, the localization to subcellular compartments, or
the interaction with binding partners. For PTEN to fulfill its
broad mechanisms of action ranging from regulation of pro-
liferation to the establishment of defined neuronal circuits, it
needs to be finely tuned both temporally and spatially. Interaction
with PIP2/PIP3-rich plasma membrane domains is apparently
an important feature of PTEN as a PIP3 phosphatase and we
begin to form a comprehensive model of how this interaction
is regulated. In addition, a surprising aspect of many recent
findings has been that PTEN can be found in different cellular
organelles. In this review, we focus specifically on the mecha-
nisms of PTEN’s association and recruitment to membranes, the
function of PTEN in different subcellular compartments, how
PTEN localizes in these specialized regions and why understand-
ing the regulation of PTEN in these defined localized areas has
become increasingly important in the context of neurological
diseases.
MECHANISMS OF PTEN CELL MEMBRANE ASSOCIATION
AND RECRUITMENT
PHOSPHOLIPID-SPECIFIC FUNCTIONS DURING ASSOCIATION OF PTEN
WITH CELL MEMBRANES
PTEN has been characterized as a highly plastic protein with
strong intramolecular interactions and conformational changes
that result from posttranslational modifications but also can
occur as a consequence of interactions with other proteins or
lipids. Under basal conditions, small concentrations of PTEN
dynamically interact with the plasma membrane, a process that
is abrogated following deletion of the N-terminal PBM (Vazquez
et al., 2006). Distinct roles for the acidic phospholipids phos-
phatidylserine (PS), PIP2, and PIP3 in regulating PTEN at the
membrane have been demonstrated.Whilst PIP2 interaction with
the PBM seems to be the primary determinant of PTEN’s plasma
membrane localization (Rahdar et al., 2009; Shenoy et al., 2012),
PS has been shown to support electrostatic attraction within
the protein-membrane interface primarily via the C2 domain
(Shenoy et al., 2012). Thus, PS and PIP2 appear to act syner-
gistically in driving PTEN membrane interaction (Shenoy et al.,
2012). PIP3, on the other hand, which binds to the phosphatase
domain, does not appear to be a key determinant of PTEN’s
membrane association, at least when presented at physiological
concentrations (Shenoy et al., 2012).
REGULATION OF PTEN MEMBRANE ASSOCIATION BY
CONFORMATIONAL CHANGES
To date, the model that best explains the accessibility of PTEN
to membranes suggests the presence of PTEN in two basic con-
formations, one of which is closed and the other open (Vazquez
and Devreotes, 2006). The closed conformation is induced by an
intramolecular association of the PTEN C-tail and part of the
PTEN C2 domain (Figure 1B). Induction of the closed confor-
mation is a process that occurs preferentially following phospho-
rylation of the PTEN C-tail (Odriozola et al., 2007; Rahdar et al.,
2009; Ross and Gericke, 2009; Shenoy et al., 2012; Bolduc et al.,
2013). Consequently, the open conformation of PTEN is thought
to be unphosphorylated on the C-tail cluster, or at least to be
less so. PTEN interactions with membranous PS and PIP2 may
also induce conformational changes (Redfern et al., 2008; Shenoy
et al., 2012), and it has been proposed that other secondary post-
translational modifications, such as sumoylation may provide a
positive signal for PTEN membrane association (Huang et al.,
2012). Therefore, levels of phosphorylation of the PTEN C-tail
cluster at S/T 380–385, although highly informative, may not
always faithfully report on PTEN’s activation state.
REGULATION OF PTEN MEMBRANE RECRUITMENT BY INTERACTING
PROTEINS
The recruitment of PTEN to membranes is further dictated
through association with other proteins (Song et al., 2012). In this
respect, transmembrane, peripheral membrane, and membrane-
associated scaffold proteins that interact with PTEN are partic-
ularly important in positioning PTEN within close proximity to
the membrane. In effect, such protein-protein interactions prime
PTEN function toward membranous substrates (Sumitomo et al.,
2004; Wu et al., 2007). Examples include the transmembrane
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protein NEP (Neutral Endopeptidase), which binds the phos-
phorylated PTEN C-tail via a highly positively charged cytosolic
domain and recruits the phosphatase to the plasma membrane,
enhancing both PTEN protein stability and activity (Sumitomo
et al., 2004). PTEN has been also shown to interact with plasma
membrane receptors of the tyrosine kinase andG protein-coupled
receptor families, although it is not always clear if these inter-
actions are direct (Sanchez et al., 2005; Fenton et al., 2012; Cao
et al., 2013). In addition, several PDZ domain-containing pro-
teins interact with the C-terminal PTEN PDZ-binding motif and
recruit PTEN to the plasmamembrane (Wu et al., 2000; Von Stein
et al., 2005; Jurado et al., 2010; Molina et al., 2012; Terrien et al.,
2012). PTEN-PDZ domain interactions may also serve in shift-
ing PTEN into the open “active” conformation by sequestering
the PTEN C-tail away from interacting with the C2-domain and
unmasking the PTEN membrane-binding regions (Vazquez and
Devreotes, 2006). However, PTEN recruitment tomembrane pro-
teins may also provide efficient “off”-switches for PIP3 hydrolysis
by sequestering PTEN away from its substrate.
Membrane associated PTEN interacting proteins have fur-
ther been described as PTEN adaptor proteins, since several
of these facilitate PTEN’s recruitment to activated receptors
and places of highly restricted production of PIP3. Examples
include NHERFs (Na(+)/H(+) exchanger regulatory factors)
or β-arrestins, which recruit PTEN to growth factor receptors
(Lima-Fernandes et al., 2011; Molina et al., 2012). Interestingly,
NHERF1, besides binding PTEN, also associates with the promi-
nent Akt phosphatase PHLPP1 (PH domain and Leucine-rich
repeat Protein Phosphatase), which leads to a synergistic atten-
uation of both PI3K-mediated PIP3 production as well as down-
stream Akt pathway activity (Molina et al., 2012). Efficient PI3K
signaling feedback regulation during acute receptor tyrosine
kinase signaling can be achieved by co-recruitment of PTEN with
the regulatory subunit of PI3K class I enzymes, p85α (Chagpar
et al., 2010). In some of the interactions, the recruitment of PTEN
to signaling complexes appears to be agonist-induced (Sanchez
et al., 2005; Fenton et al., 2012). Therefore, a clear distinc-
tion can be made between PTEN-membrane protein interactions
that appear to be constitutive and interactions that are agonist-
induced. One can only surmise the latter to be spatially restricted
to specific sites of active PI3K signaling.
PTEN, LIPID RAFTS, AND ASSOCIATED MICRODOMAINS
A further mode of membrane PTEN recruitment is orchestrated
by lipid rafts or detergent-resistant membrane fractions in dif-
ferent cells such as cortical neurons, oligodendroglioma, and
pheochromocytoma cell lines (Cheung et al., 2004; Goswami
et al., 2005; Choy et al., 2006). Lipid rafts are specialized mem-
brane microdomains involved in the compartmentalization of
cellular processes and act as organizing centers for the assembly
of signaling molecules. Two types of lipid rafts have been pro-
posed: planar lipid rafts and caveolae. Planar rafts are defined
as being continuous with the plane of the plasma membrane,
whilst caveolae invaginate with the help of caveolin proteins.
Planar rafts contain flotillin and are found in neurons where
caveolae are absent. Both types of lipid rafts demonstrate sim-
ilar lipid compositions that are enriched in cholesterol and
sphingolipids. Lipid raft association of PTEN in neurons appears
to be related to apoptosis either induced by lactacystin (Choy
et al., 2006), or by treatment with N-acetylsphingosine (C2-
ceramide) (Goswami et al., 2005). On the one hand, PTEN’s
recruitment to flotillin-rich plasma membrane domains was
demonstrated during lactacystin-induced apoptosis in cortical
neurons and verified by immunogold-TEM (Choy et al., 2006).
On the other hand, PTEN has been found to associate with cave-
olin in immunoprecipitation experiments, which could account
for recruitment to caveolin-rich subcellular fractions in caveolae-
positive cell types (Caselli et al., 2002). In another study, PTEN
was found to localize into the non-raft region of the plasma
membrane (Gao et al., 2011). This localization was essential
for allowing proper and robust activation of PDK1 and Akt in
response to occurrence of growth factors receptor activation in
the lipid raft region (Gao et al., 2011). Indeed, forced localization
of constitutively activated PTEN to lipid rafts, or treatment with
C2-ceramide (Goswami et al., 2005), was found to prevent growth
factor-induced lipid raft restricted activation of PDK1 and Akt
(Gao et al., 2011). Together, these studies suggest that activators
and inhibitors of the PI3K pathway might be segregated to dis-
tinct sub-compartments at the level of the plasma membrane in
dependence of the lipid raft composition. Nevertheless, the exact
targeting mechanisms that segregate neuronal PTEN from lipid
rafts, or that recruit PTEN into lipid rafts upon signaling, are
currently unknown.
PTEN MEMBRANE ASSOCIATION IN NEURONS
PTEN and its associated PI3K signaling pathway have been shown
to be particularly relevant in neurons during the control of cell
growth, division, survival, and differentiation, in order to produce
highly polarized neuronal morphologies with exquisite specializa-
tions such as growth cones and synapses. The proper localization
of PTEN at the membrane is a key factor in the establish-
ment of a PIP3/PIP2 gradient and the recruitment of important
components necessary for the formation of growth cones and
dendritic spines. PTEN is present in most, if not all, neurites
during early neurite outgrowth, and in axons and dendrites in
mature neurons. In particular, PTEN seems to be maintained
at the microtubule-rich, central domain of growth cones with
relatively low levels seen in the peripheral growth cone domain
with its actin-rich filopodia and lamellipodia (Chadborn et al.,
2006; Kreis et al., 2013; see Figure 2). Similarly, whilst PTEN-loss
induces dramatic rearrangements in dendritic spine morphology
and affects synaptic transmission, endogenous levels of PTEN
are barely detectable in this neuronal compartment (Figure 3;
Fraser et al., 2008; Kreis et al., 2010, 2013). These observations
suggest that, specifically in neurons, PTEN may be sequestered
away from the cell membrane and selectively recruited to the
membrane under certain conditions. PTEN localization at the
growth cone membrane has been shown to be mainly involved
in the regulation of a PIP3 pool to induce chemorepulsion. On
one hand, during Sema3A-induced growth cone collapse, neurite
retraction, and chemorepulsion in dorsal root ganglion (DRG)
growth cones, PTEN is recruited transiently and accumulates at
the membrane, leading to decreases in PIP3 levels and an antag-
onistic effect on the PI3K signaling pathway (Chadborn et al.,
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FIGURE 2 | Subcellular targeting and dynamic regulation of PTEN in
neurons: Schematic illustration demonstrating dynamic distributions of
PTEN in different neuronal compartments. (A) During neuronal
development, PTEN is enriched in the axons and dendrites. Here, PTEN is
thought to function in the regulation of growth cone dynamics during axonal
navigation, in particular by inhibiting neurite outgrowth or mediating growth
cone collapse responses. Consequently, PTEN-loss results in increased
regenerative growth of axons in spinal cord injury models as well as
protecting neurons during degeneration. (B) In mature CNS neurons PTEN is
found in the dendrite. During NMDAR-dependent dendritic spine plasticity
(long-term depression, LTD), PTEN translocates deep into the spine and
anchors to the postsynaptic density. PTEN, by targeting membranous PIP3,
also contributes to the dynamic changes in spine morphology during synapse
development and plasticity. These synapse specific functions are thought to
contribute to neurodevelopmental disorders such as autism, epilepsy, and
mental retardation. (C) Nuclear PTEN has been reported to mediate neuronal
survival or specifically induces apoptotic responses. Movement to the
nucleus has been reported to occur during ischemia, traumatic brain injury,
and degeneration; however, specific functions of these translocations are not
clear.
2006). Along this vein, it has been suggested that PTEN is required
for the activity of a number of established neurite outgrowth
inhibitors, such as Sema3A, Sema4D. and Myelin-associated gly-
coprotein (MAG) in DRGs, hippocampal, cortical, and spinal
neurons (Chadborn et al., 2006; Oinuma et al., 2010; Perdigoto
et al., 2011; Henle et al., 2013). On the other hand, polarized
increases in PIP3 at the leading edge of growth cones is an
essential element of axonal growth and growth cone attraction
(Henle et al., 2011). Accumulation of PIP3 has been seen also in
axonal microdomains proximal to the growth cone. These PIP3
microdomains are induced byNGF (Nerve growth factor) in DRG
neurons and they seem to be necessary for the formation of axonal
F-actin patches that support the generation of axonal filopodia
(Ketschek and Gallo, 2010). Similarly, optogenetic control of PIP3
accumulation can induce the formation of active mobile F-actin
lamellipodia-like structures in growth cones or along proximal
axonal segments (Kakumoto and Nakata, 2013). These PIP3-rich
membrane domains can be endocytosed, restricting downstream
signaling components and thus leading to the modification of
the size and function of the growth cone. Local accumulation of
PIP3 is also important for axonal growth. Under basal conditions
on a permissive laminin substrate, PIP3 levels are concentrated
within the peripheral domain and fluctuate stochastically (Henle
et al., 2013). However, upon exposure to chemoattractive growth
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FIGURE 3 | Anti-PTEN antibodies do not always faithfully report on
subcellular distributions of PTEN. Cortical neurons isolated from
PTENflox/flox mice were transduced with control or Cre-expressing viruses at
13 days in vitro (DIV). Neurons were fixed with 4% parafolmaldehyde at
25DIV, permeabilized with 0.1% Triton X-100 and stained with Phalloidin to
visualize F-actin and anti-PTEN antibodies 138G6 (rabbit monoclonal from Cell
Signaling Technology) and A2B1 (mouse monoclonal from Santa Cruz
Biotechnogy). PTEN as detected with 138G6, (1:400 dilution) is highly
enriched in the neuronal soma and dendrites, but it is largely absent in
dendritic spines (first row). Cre-mediated recombination induced a PTEN-loss
that resulted in well-established morphological changes in neuronal
morphology including, for example, hypertrophy of the soma. In Cre-treated
neurons, PTEN labeling using 138G6 was absent (second row), whilst the
mouse A2B1 anti-PTEN antibody (third row) still retained strong labeling
(although used at a high dilution of 1:1000). Note that the faint nuclear
staining in control and Cre-recombinase treated neurons in F-actin images is
due to nuclear RFP and RFP-Cre expressed, respectively, in these cells. Scale
bar = 20μm.
guidance cues, PIP3 accumulation occurs in a polarized fashion
toward the source of the cue (Henle et al., 2011). Thus, a feasible
mechanism of PTEN functioning in neurons maybe to reinforce
or re-sensitize PI3K-dependent signaling during growth factor
promoted axonal elongation, as well as mediating axonal growth
inhibition (Figure 2).
Using PIP3-specific Fluorescence resonance energy transfer
(FRET) sensors to study the role of PIP3 at the synapse compart-
ment, Ueda and Hayashi showed that PIP3 is primarily enriched
in spines and not in dendritic shafts (Ueda and Hayashi, 2013).
Upon chemical inhibition of PTEN, PIP3 was seen to accumulate
preferentially in dendritic shafts rather than in spines, indicating
that PTEN activity in the shaft region is higher while the oppo-
site appears to apply for PI3K activity (Ueda and Hayashi, 2013).
Small amounts of PTEN are present in the cytosolic compart-
ment of spine heads, and in the plasma membrane away from
the postsynaptic density (PSD) (Jurado et al., 2010). However,
following NMDAR (N-methyl-D-aspartate receptor) stimula-
tion, PTEN can be further enriched in the dendritic spine and
anchored to the PSD primarily via PDZ-dependent interactions
with PSD-95 (Jurado et al., 2010). Analysis of GFP-PTEN mobil-
ity in the spine has suggested that at least half of the PTEN spine
pool is stable under basal conditions but, upon acute NMDAR
activation there is increased mobility and eventually retention of
PTEN into the spine (Jurado et al., 2010). Interestingly, deletion
of the PDZ-binding domain of PTEN still results in increased
mobility but abolishes the retention of PTEN into the spine
(Jurado et al., 2010). It is conceivable that there is a basal diffu-
sion of a small PTEN pool into spine that can then be retained
and further targeted to the PSD in an activity-dependent man-
ner. Thus, it appears that regulated PTEN localization in the spine
and the PSD may be important for synapse-specific modulation
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of PIP3 signaling during synaptic plasticity. The recruitment and
activation of PTEN at the membrane of neurons are important
elements to the establishment of a localized PIP3/PIP2 balance
necessary for specialized regions of the neurons to form and
function in a required way. Other PIP3-independent roles of
PTEN may also be important in this neuronal compartment,
together they converge to allow the correct functioning of the
synapse.
EVIDENCE FOR PTEN ASSOCIATION WITH INTERNAL
MEMBRANE COMPARTMENTS
Based on the characteristic enrichments of PIP2 and PS in the
inner leaflet of plasma membranes, the activity of membrane-
bound PTEN is mostly confined to this compartment. However,
a unique feature of PTEN is its ability to interact also with inter-
nal membrane containing organelles. The specific roles of PTEN
at these membrane systems remains poorly understood. Because
of the established link of these organelles to the pathology of dif-
ferent neurological conditions, we briefly review these relatively
recent findings here.
PTEN AND MITOCHONDRIA MEMBRANES
PTEN localizes to mitochondria (Zhu et al., 2006; Zu et al.,
2011; Bononi et al., 2013). In primary rat hippocampal neu-
rons, PTEN’s association to mitochondria membranes has been
demonstrated by both immunohistochemistry and biochemical
fractionation experiments, a localization that has been shown
to increase during apoptotic stimuli, for example using stau-
rosporine (Zhu et al., 2006). PTEN was found to interact with
a member of the Bcl-2 (B-cell lymphoma 2) gene family, BAX,
in co-immunoprecipitation experiments and this protein-protein
interaction has been attributed to regulating the recruitment of
PTEN to the outer mitochondrial membrane, at least during the
initial phases of the response. A similar association of PTEN with
Bax and mitochondria has been described recently in myocytes
during ischemia-reperfusion (Zu et al., 2011). Following induc-
tion with apoptotic stimuli, BAX becomes organelle membrane-
associated, in particular, with mitochondrial membranes. On this
basis, PTEN’s transient association with BAX has been connected
to mitochondria-dependent apoptotic death. But, as yet, specific
mechanistic insight into a proposed PTEN connection has not
been achieved.
PTEN AND ENDOPLASMIC RETICULUMMEMBRANES
A recent study demonstrated the presence of PTEN at the endo-
plasmic reticulum (ER) with apparent specific enrichment in
mitochondria-associated membranes (MAMs) (Bononi et al.,
2013).MAMs are distinct ER domains that support physical inter-
action between the ER and mitochondria and that are thought
to be essential for efficient supply of Ca2+ from the ER to mito-
chondria (Fujimoto and Hayashi, 2011). Accordingly, they play
major roles in both Ca2+-regulated mitochondrial bioenergetics
and sensitivity to apoptosis, amongst other processes (Fujimoto
and Hayashi, 2011). Sub-cellular localizations of PTEN to the
ER and to MAMs were verified by immunostaining and bio-
chemical fractionation experiments. An interaction of PTEN, as
well as of Akt, with the ER inositol 1,4,5-trisphosphate receptor
(InsP3R) at the ER-MAMmembranes—the membrane glycopro-
tein complex that acts as the Ca2+-channel activated by inositol
trisphosphate—was detected (Bononi et al., 2013). Importantly,
apoptotic stimuli enhanced the recruitment of PTEN to these
InsP3R complexes, leading to reduced Akt activity and Akt-
dependent InsP3R phosphorylation and resulting in an increased
Ca2+ release (Bononi et al., 2013). Specific targeting of PTEN to
the ER was found to be sufficient to enhance ER-to-mitochondria
Ca2+ transfer and sensitivity to apoptosis. Notably, this mecha-
nism was dependent on the PTEN protein phosphatase activity
and not the PTEN lipid phosphatase activity (Bononi et al., 2013).
Although the mechanism of PTEN’s recruitment to MAMs and
non-MAM ER membranes remains unclear, it is likely that the
PTEN-InsP3Rs association is involved. Whilst small PIP3 pools
are present in ER membranes and mitochondria (Lindsay et al.,
2006), no evidence has been provided that suggests PTEN actively
regulates these pools (Bononi et al., 2013). Given the proxim-
ity of MAMs to mitochondria, it is also possible that some of
the mitochondria-associated PTEN functions could be related
to its localization in the MAMs. Interestingly, MAMs have been
detected in neurons and synaptosomes and are important for
neuronal ER-mitochondria communication as well as neuronal
survival (Hedskog et al., 2013). Thus, PTEN targeted to ER-
MAMs in neurons could regulate mitochondria functions such
as Ca2+ homeostasis or induce apoptotic signaling as implicated,
for example, in neurodegenerative diseases such as Alzheimer’s
disease (AD).
PTEN, EXOSOMES, AND PTEN-LONG ISOFORM SECRETION
Exosomes are bona fide secreted membrane organelles that con-
tain cytosolic or endosomal proteins, and that are thought to
provide essential intercellular communication. In this manner,
exosomes serve as mediators to convey proteins, lipids and genetic
information from one cell to another. Exosomes are formed in
the cell in multivesicular endosomes that can fuse to the mem-
brane to release their contents (Raposo and Stoorvogel, 2013).
Recently, it has been shown that PTEN can be secreted in exo-
somes, exported in the extracellular compartment and taken up
by recipient cells. This sequence of events has raised the excit-
ing possibility that PTEN has non-cell-autonomous functions
(Putz et al., 2012). Exosome-mediated PTEN secretion has been
shown to require Ndfip (Nedd4 family interacting protein-1), an
adaptor protein for E3 ubiquitin ligases, and an intact ubiquiti-
nation residue at PTEN K13 (Putz et al., 2012). PTEN loaded
exosomes can inhibit the PI3K signaling pathway in recipient cells
and decrease cellular proliferation (Putz et al., 2012). A further
cellular strategy shown to generate secreted forms of PTEN is
the presence of an additional sequence of 173 amino acids at the
PTEN N-terminus (Hopkins et al., 2013). This PTEN-long phos-
phatase, translated from an alternative initiation codon upstream
of the normal initiation codon, contains a secretion signal and a
cell penetrating sequence and has the property to interact with
cell surface proteins. When added as exogenous agent to cells in
culture or injected intraperitoneally in mice, PTEN-long was able
to decrease the activity of the PI3K signaling pathway. In addi-
tion, when injected in tumor mouse models, PTEN-long was able
to induce tumor regression (Hopkins et al., 2013).
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The mechanisms underlying PTEN secretion require further
exploration and may turn out to depend on the cell status or the
cell type. Exosomes have been detected in neurons and glial cells,
suggesting that they may serve as regulators of synaptic plasticity
or participate in the propagation of pathological proteins respon-
sible for neurodegenerative diseases (Chivet et al., 2013; Frühbeis
et al., 2013). PTEN-loaded exosomes or PTEN-long expression
could thus allow different intercellular exchanges within different
brain regions, thereby modulating, for example, local changes in
PI3K-mediated synaptic plasticity. Both forms of secreted PTEN
appear to be physiologically and clinically significant as they can
be readily detected in human blood (Gabriel et al., 2013; Hopkins
et al., 2013).
NUCLEAR FUNCTIONS OF PTEN
Despite its well-established role in antagonizing PI3K signaling
at the plasma membrane, PTEN has also been characterized as
present in the nucleus of a number of cells, including fully dif-
ferentiated neurons (Gimm et al., 2000; Lachyankar et al., 2000;
Chadborn et al., 2006) (Figure 3). It appears that nuclear local-
ization of PTEN is a dynamic process that correlates with cell
cycle progression and/or the cellular differentiation state, and that
it may be highly context dependent (Lian and Di Cristofano,
2005; Planchon et al., 2008; Song et al., 2012). In several can-
cer types, nuclear localization is a contributory factor to PTEN’s
tumor suppressor activity, for example, by maintaining chro-
mosomal integrity (Shen et al., 2007), and regulating cellular
survival (Chung et al., 2005; Gil et al., 2006), cell cycle, and DNA
repair responses (Shen et al., 2007; Song et al., 2011; Bassi et al.,
2013). Nuclear PTEN can also directly interact with p53 and
alter transcriptional activity (Freeman et al., 2003). Importantly,
recent studies have highlighted the importance of nuclear PTEN
also in neurons, particularly in the context of neuronal sur-
vival (Figure 2). PTEN has been found to translocate to the
nucleus during ischemia, traumatic brain injury (TBI) and dur-
ing NMDA-induced excitotoxicity (Howitt et al., 2012; Goh et al.,
2013; Zhang et al., 2013). In NMDA-challenged cortical neu-
rons, translocation of PTEN to the nucleus is a delayed event,
peaking at 6–9 h after treatment and with a decline after 24 h
(Zhang et al., 2013). However, a persisted localization of PTEN
in the nucleus of cells after 24 h has been observed in TBI mod-
els in cortical neurons (Goh et al., 2013). Whether nuclear PTEN
functions as a pro-survival protein or whether it contributes to
cell death remains controversial. For example, nuclear transloca-
tion of PTEN following TBI or cerebral ischemia (Howitt et al.,
2012; Goh et al., 2013) does not seem to correlate with increased
apoptosis in vivo; rather, it has been proposed that it might be a
generic neuroprotective response of stressed neurons (Goh et al.,
2013). Yet, in NMDA-challenged cortical neurons, inhibition of
PTEN’s nuclear translocation by a peptide designed to antago-
nize K13-ubiquitination of PTEN appears to be neuroprotective
(Zhang et al., 2013). Further experiments are urgently needed to
clarify the functions of nuclear PTEN in neurons since genetic
or pharmacological PTEN inhibition is discussed as a promising
approach to increasing neuroprotection in various settings (Ding
et al., 2013; Mao et al., 2013). But how does PTEN function in the
nucleus? Currently, there seems to be substantial evidence that
at least some (if not most) of nuclear functions do not directly
involve PTEN’s PIP3 phosphatase activity (Song et al., 2012). PIP3
is present in the nucleus, as well as different PI3K isoforms and
activated Akt, yet a detailed ultrastructural study suggested that
the nuclear pool of PIP3 is not sensitive to hydrolysis by PTEN
(Lindsay et al., 2006). Furthermore, given that PTEN’s activity
toward PIP3 requires structural interactions with membranes, it
would be hard to reconcile this taking place in membrane-free,
subnuclear compartments, where most of the nuclear PIP3 pool
is located. Interestingly, a recent study suggested the possibil-
ity of different conformations adapted by cytosolic and nuclear
PTEN, which may suggest phosphatase-independent functions
for nuclear PTEN (Moncalero et al., 2011). Indeed, several
nuclear PTEN functions that are relevant to its tumor suppressing
role, such as control of the activity of the Anaphase Promoting
Complex/Cyclosome (APC/C) and maintaining chromosomal
integrity, do not require its lipid nor its protein phosphatase activ-
ity (Shen et al., 2007; Song et al., 2011). Other nuclear PTEN
functions, however, have been shown to require at least its pro-
tein phosphatase activity (Bassi et al., 2013). Interestingly, NMDA
treatment of cortical neurons, leads to nuclear PTEN transloca-
tion, resulting in decreases in PIP3 levels and Akt phosphoryla-
tion in this compartment (Zhang et al., 2013). However, whether
nuclear PTEN in neurons is indeed active against nuclear PIP3
and thus regulates survival by inhibiting Akt remains to be tested.
NUCLEAR TARGETING OF PTEN
PTEN interacting proteins like MVP (Major Vault protein),
the GTPase Ran, or the protein PNUFTS (a nuclear targeting
subunit of PP1) may have a function in transporting or seques-
tering PTEN to the nucleus (Chung et al., 2005; Gil et al.,
2006; Kavela et al., 2013). Nevertheless, the mechanisms of
PTEN nucleo-cytoplasmic shuttling appear to primarily involve
posttranslational modifications such as monoubiquitination or
sumorylation (Trotman et al., 2007; Bassi et al., 2013). The
phosphorylation of the C-terminus of PTEN has also been sug-
gested to influence the cytoplasmic and nuclear localization of
PTEN, which may be related to the conformation of PTEN
modifying its potential to be ubiquitinated or to localize to mem-
branes enriched in ubiquitin ligases (Vazquez et al., 2001; Gil
et al., 2006; Maccario et al., 2010). Two PTEN monoubiqui-
tination sites, K289 and K13, have been found to contribute
to the localization of PTEN to the nucleus (Trotman et al.,
2007; González-Santamaría et al., 2012; Zhang et al., 2013).
Particularly in neurons, K13 alone appears to be important for
PTEN nuclear localization (Zhang et al., 2013). However, K13
is also important for membrane association of PTEN as it is
part of the PBM region (Walker et al., 2004; Figure 1B). Early
studies indicated that the E3 ubiquitin ligase Nedd4 (neural
precursor cell-expressed developmentally downregulated gene 4)
can regulate monoubiquitination of PTEN and regulate PTEN’s
import into the nucleus (Trotman et al., 2007). Ndfip1, an adap-
tor for Nedd4-mediated ubiquitination and a direct binding
partner of PTEN (Mund and Pelham, 2010) is also necessary for
nuclear localization of PTEN in neurons (Howitt et al., 2012). A
PTEN-deubiquitinating enzyme, HAUSP (herpesvirus-associated
ubiquitin-specific protease) may serve in the deubiquitination of
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PTEN and its shuttling out of the nucleus (Song et al., 2008). To
date, most Nedd4/PTEN studies in neurons have focused on the
role of polyubiquitination in controlling PTEN abundance by the
ubiquitin-proteasome system and identified that PTEN protein
levels can be correlated with changes in survival or axonal growth
and branching (Christie et al., 2010; Drinjakovic et al., 2010; Kwak
et al., 2010).
PTEN LOCALIZATION AND THE CYTOSKELETON
In developing neurons, PI3K, PTEN, and Akt downstream signal-
ing pathways are essential for most aspects of neuronal polarity,
such as neurite outgrowth, axon and dendrite specification,
growth cone guidance and migration (Waite and Eickholt, 2010).
The intimate relationship of phosphoinositides and their impact
on actin cytoskeleton dynamics stems from the fact that many
proteins that are known to affect the actin-based cytoskeleton
are acutely regulated by PIP2 and/or PIP3 (Yin and Janmey,
2003; Di Paolo and De Camilli, 2006). Indeed, PIP3 is regarded
as a master regulator of Rho and Arf family-specific GEFs/GAPs
(Hawkins et al., 2006) and its turnover is linked to initiation of
cell migration and actin cytoskeleton reorganization, including,
for example, the formation of structures like F-actin patches,
lamellipodia and filopodia (Gallo, 2013; Kakumoto and Nakata,
2013; Karunarathne et al., 2013). The local balance between PIP2
and PIP3 may be essential during initiation and emergence of
filopodia, as suggested by axonal filopodia biogenesis models
(Gallo, 2013). Initial localized synthesis of PIP3 in membrane
microdomains precedes and marks the position of actin patches
(Ketschek and Gallo, 2010; Spillane et al., 2011). As PIP3 levels
decline, increases in PIP2 may recruit the molecular machinery
driving the emergence of a filopodium from the actin patch
(Gallo, 2013). According to this model, dynamic hydrolysis
of PIP3 to PIP2 by PTEN might be instrumental. However,
analysis by immunostaining or live imaging of fluorescent
PTEN constructs has rarely shown constitutive localization
of PTEN in prominent F-actin structures, for example in the
lamellipodia-rich leading edge of chemoattracting cells or in
the peripheral zone of migrating growth cones (Li et al., 2005;
Chadborn et al., 2006; Kreis et al., 2010). This is usually regarded
as a sequestration of PTEN away from these sites in order to allow
a steep PIP3 gradient to be formed and maintained, particularly
during cell migration. In the case of growth cones and processes
of neurons and neuronal cells, PTEN instead localizes rather
prominently with microtubules (Chadborn et al., 2006) and
recruitment to specific F-actin rich sub-plasmalemma domains
may be driven by active transport mechanisms (Van Diepen et al.,
2009; Kreis et al., 2010).
PTEN function has also been shown to be controlled by
regulators of F-actin reorganization such as Rho family GTPases,
Rac and Rho. P-Rex2a, a prominent Rac activator that is activated
by PIP3, inhibits PTEN PIP3 phosphatase activity by direct
interaction (Fine et al., 2009; Hodakoski et al., 2014), while
active RhoA is thought to stimulate PTEN’s PIP3 phosphatase
activity, by ROCK-mediated phosphorylation of PTEN (Li et al.,
2005). There is further a substantial degree of crosstalks and
feedback loops embedded within the PI3K-PTEN-Rac/Rho
GTPase network. Membranous PIP3, is able to activate RacGEFs,
yet Rac is unique amongst Rho family GTPases in that it can
directly activate specifically p110β PI3K, the only Ras-insensitive
PI3K class I isoform (Fritsch et al., 2013). Furthermore, p110δ
PI3K can inhibit PTEN via RhoA/ROCK (Rho-associated protein
kinase) (Eickholt et al., 2007; Papakonstanti et al., 2007). Another
feature that adds complexity to the relationship of PTEN and
the F-actin cytoskeleton is due to the fact that PIP3 can also
be metabolized to PI3,4P2 by SHIP2 and other 5-phosphatases
(Leslie et al., 2008). PI(3,4)P2 by itself is involved in many
aspects of F-actin cytoskeleton reorganization by interaction
with its specific effectors such as lamellipodin (Krause et al.,
2004; Yoshinaga et al., 2012). Thus, PTEN may work in concert
with 5-phosphatases in order to achieve precise regulation of the
timing and extent of PI3K-generated PIP3 and PI3,4P2 at active
sites of F-actin remodeling during neurite extension or growth
cone dynamics (Aoki et al., 2007).
PTEN by itself interacts with actin cytoskeleton structural,
accessory, or regulatory proteins, although, in most cases, the
direct effects of PTEN activity or actin cytoskeleton function is
not known. For example, PTEN was recently identified as part
of a plasma membrane-associated actin remodeling complex
composed of actin, gelsolin, and EPLIN (Epithelial Protein
Lost In Neoplasm) (Kim et al., 2011b). Although it’s unclear
whether PTEN directly regulates the activity of the proteins in
this complex, this association is proposed to be functional in
regulating cell size checkpoint control in irradiated cells (Kim
et al., 2011b). Early studies have shown that PTEN can regulate
the integrin-mediated cell spreading and the formation of focal
adhesions possibly by binding to focal adhesion kinase (FAK) and
the downregulation of FAK tyrosin phosphorylation (Tamura
et al., 1999, 1998). In addition, binding of PTEN to Bazooka/Par3
(Von Stein et al., 2005), can result in its recruitment to actin
rich regions and the establishment of apical membrane identity
by dephosphorylating PIP3 into PIP2 (Shewan et al., 2011).
Interestingly, Bazzoka/Par3 can recruit PTEN via its PDZ3
domain and thus could relocate PTEN to PIP3/PIP2-rich
domains recognized by its PDZ2 domain (Wu et al., 2007).
Drebrin (Developmentally regulated brain protein) is another
recently identified interacting protein of PTEN, which binds to
actin filaments (Kreis et al., 2013). Drebrin is known to change
the property of the actin cytoskeleton to control the formation
of filopodia (Hayashi et al., 1996), potentially involving CDK5
(Cyclin-dependent kinase 5) mediated phosphorylation at S142
(Worth et al., 2013). Phosphorylation at another Drebrin site,
S647, is targeted by PTEN in a PI3K-independent fashion
in response to signals that induce a dynamic remodeling of
the cytoskeleton (Kreis et al., 2013). Therefore, it has become
increasingly clear that not all cytoskeleton-dependent processes
regulated by PTEN depend on the PIP3 lipid phosphatase activity.
As described in previous sections, PTEN is dynamically local-
ized to specialized sub-cellular compartments and organelles.
This dynamic recruitment implies a tight temporal and spatial
regulation and current evidence highlights the contribution of
PTEN protein modifications and formation of distinct protein-
protein interactions in this process. Given the wide implication
of PTEN in various pathological conditions, in the following
sections, we attempt to summarize and emphasize the putative
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significance of compartmentalized PTEN pools in the progression
of different neurodevelopmental diseases and neurodegenerative
conditions.
PTEN AND NEURODEVELOPMENTAL DISEASES
PTEN HAMARTOMA TUMOR SYNDROME (PHTS)
The term, PTEN hamartoma tumor syndromes (PHTS), refers to
a collection of clinically distinct syndromes molecularly defined
by germline PTEN mutations. These include Cowden syndrome
(CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syn-
drome (PS), and Proteus-like syndrome (PSL) (Eng, 2003; Mester
and Eng, 2013). CS is a multiple hamartoma syndrome with a
high risk for benign and malignant tumors. BRRS is associated
with macrocephaly, intestinal hamartomatous polyposis, lipo-
mas, and pigmented macules of the glans penis. PS is a complex
and highly variable disorder involving congenital malformations
and hamartomatous overgrowth of multiple tissues. PSL, in con-
trast, appears relatively undefined. It refers to individuals with
significant clinical features of PS who do not meet the diagnostic
criteria for this syndrome. Importantly, up to 85% of individuals
who meet the diagnostic criteria for CS and 65% of individuals
with a clinical diagnosis of BRRS have detectable PTEN muta-
tions (Eng, 2003). PTEN mutations appear also to be present in
patients with PL and PLS, yet it has been suggested that patients
with bona fide PS did not have PTENmutations (Mester and Eng,
2013). Nevertheless, PI3K/PTEN/Akt/mTORC1 signaling seems
to have a dominant role in the neurodevelopmental and over-
growth defects associated with this group of syndromes (Mester
and Eng, 2013). Indeed, recent studies have reported the pres-
ence of activating mutations in Akt1 in PS (Lindhurst et al., 2011)
and activating mutations in PIK3CA and Akt1 in a subset of CS
(Orloff et al., 2013).
The majority of PTEN missense mutations found in PHTS
occur in the phosphatase domain of PTEN (Eng, 2003; Mester
and Eng, 2013) and most of these result in full or partial inacti-
vation of PTEN’s PIP3 activity (Eng, 2003; Rodríguez-Escudero
et al., 2011). One particular mutation, G129E, originally iden-
tified in two independent CS kindreds, abolishes only the lipid
phosphatase activity of PTEN, whilst the activity of the protein
phosphatase is preserved (Myers et al., 1998). This character-
istic has been instrumental in studying PIP3-dependent and
-independent roles of PTEN (Raftopoulou et al., 2004; Tibarewal
et al., 2012; Zhang et al., 2012a). Several PTEN mutations occur
also in the C-terminal part of the protein (examples are F241S,
P246L, K289E, R335L, V343E, L345V, F347L in the C2 domain).
Some of these have been shown to reduce catalytic activity and
membrane association (Rodríguez-Escudero et al., 2011) and/or
have been shown to interfere with posttranslational modifica-
tions that are crucial for subcellular targeting of PTEN to the
nucleus (Trotman et al., 2007). Phenotypes that can be associated
with PTEN germline mutations also include Lhermitte-Duclos
disease (LDD). Most, if not all, adult-onset LDD (dysplastic
gangliocytoma of the cerebellum, a hamartomatous overgrowth
known to be a feature of CS) can be attributed to mutations in
PTEN, even in the absence of other clinical signs of CS/BRRS.
However, germline PTEN mutations appear rare in individuals
with childhood-onset LDD (Eng, 2003).
The PTEN-associated neurological deficits frequently
observed in this group of syndromes are macrocephaly, devel-
opmental delay, and mental retardation. Ataxia, tremor, and
epilepsy have been also reported (Lachlan et al., 2007; Conti et al.,
2012; Mester and Eng, 2013; Pilarski et al., 2013). It should be
noted, however, that no strong genotype–phenotype correlations
are known in PHTS to date (Mester and Eng, 2013). Studies
regarding the properties of mutated PTEN in PHTS are generally
lacking, although some evidence suggests a correlation between
PHTS and PTEN defect in a specific subcellular compartment.
For example, the PTEN K289E mutation identified in CS dis-
turbs the translocate of PTEN into the nuclei of patient tissue
(Trotman et al., 2007). Another example relates to a mutation
in the C2 domain, PTEN R335V which is also responsible for
CS. This PTEN mutant enzyme retains normal levels of activity
in cells (Rodríguez-Escudero et al., 2011), but its interaction
with the lipid bilayer may be altered as suggested in a model of
PTEN membrane association (Lumb and Sansom, 2013). Active
research using molecular interaction simulation and modeling
approaches, as well as functional screening of PTEN mutations
in cell-based assays (Rodríguez-Escudero et al., 2011; Lumb and
Sansom, 2013; Nguyen et al., 2013), will no doubt prove helpful
in further clarifying the effects of PTEN mutations associated
with PHTS.
AUTISM SPECTRUM DISORDERS (ASD)
PTEN has been established as one of the genetic factors
that play a major role in autism spectrum disorders (ASD)
(Zhou and Parada, 2012). ASD serves as an umbrella term for
autism and related conditions pertinent to social-communication
deficits, and restricted and repetitive behavior diagnosed in
early childhood. Autism is also associated with sensory and
motor abnormalities, sleep disturbance, epilepsy, attention
deficit/hyperactivity disorder (ADHD)-like hyperactivity, intel-
lectual disability, and mood disorders such as anxiety and aggres-
sion (Won et al., 2013). Germline PTEN mutations have been
identified in 5–10% of autism patients, following the initial report
that approximately 20% of individuals with autism spectrum dis-
orders andmacrocephaly carry germline PTENmutations (Butler
et al., 2005). Macrocephaly is also prevalent in PTHS patients
with PTENmutations (Mester et al., 2011; Mester and Eng, 2013)
and it is one of the most frequent neuroanatomical abnormalities
(20%) observed in ASD individuals (Won et al., 2013).
Several PTEN mouse models have provided strong evidence
for a causative role of PTEN dysfunction in almost all mor-
phological, anatomical, synaptic, and behavioral manifestations
relevant to ASD. Deletion of PTEN in neural progenitor cells and
embryonic neural stem cells (Nestin-Cre:Ptenloxp/loxp) results in
increased neural stem cells proliferation, enlarged cell size, and
brain enlargement (Groszer et al., 2001). Deletion of PTEN in
GFAP (glial fibrillary acidic protein)-expressing neural progeni-
tors, astrocytes, and a large subset of hippocampal neurons, cere-
bellar granule neurons, and cortical pyramidal neurons (Fraser
et al., 2004, 2008) results in numerous structural abnormalities
such as dramatic hypertrophy of nuclei, somata, axon, and den-
dritic caliber, enlarged presynaptic terminals, as well as absence
or enlarged postsynaptic densities. Furthermore, the enlarged
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dendritic processes in Pten conditional knock out (cKO) mice
showed a substantial increase in the density of spines and abnor-
mal spine morphology (Fraser et al., 2008). Mice also developed
progressive macrocephaly, seizures, and ataxia (Backman et al.,
2001; Kwon et al., 2001). Although an increase in spine density
was also observed following PTEN shRNA (short-hairpin RNA)
treatments, there seems to be subtle difference when compared to
genetically induced PTEN-loss (Luikart et al., 2011). In the baso-
lateral amygdala and the dentate gyrus PTEN shRNA treatment
resulted in increasedmushroom spine density and spine size, with
correspondingly decreased thin protrusion density at more dis-
tal segments (Haws et al., 2014). These results suggest that rather
than inducing de novo spinogenesis per se, PTEN deletion may
interfere with normal morphological and functional maturation
of spines (Haws et al., 2014). Nevertheless, the most informative
animal model related to ASD is the NSE-Cre:Ptenloxp/loxp mouse
with postnatal deletion of PTEN in selected neuronal populations
(Dentate gyrus granule cells, CA3 hippocampal neurons, and
selected populations of cortical neurons). This PTEN cKO model
recapitulates many of the late-onset morphological and behav-
ioral abnormalities associated with autistic symptoms as these
mice exhibit macrocephaly, neuronal hypertrophy, and deficits in
hippocampus-based social and cognitive behavior, hypersensitiv-
ity to sensory stimuli, anxiety, and epileptic seizures (Kwon et al.,
2006). Notably, autism-relevant behaviors are detectable at a time
when morphological abnormalities seem relatively subtle (Kwon
et al., 2006). Subsequent studies using a tamoxifen-inducible
Nestin-Cre:Ptenloxp/loxp mouse model, in order to delete PTEN
specifically in postnatal neural stem cells in the subgranular zone
of hippocampal dentate gyrus, recapitulated the general over-
growth phenotype seen in other models and some, but not all of
the impairments associated with autism (Amiri et al., 2012).
PTEN’s role in regulating neuron morphology, gross anatom-
ical changes and behavior is largely dependent on its lipid phos-
phatase activity. As such, in all PTEN KO and knockdownmodels
studied to date, the major biochemical result of PTEN deletion
invariably observed is an enhancement in Akt/mTORC1 signal-
ing pathway activity. This is consistent with the primary defect
of PTEN loss being an increase in PIP3 production and PI3K
signaling. However, pharmacological inhibition of mTORC1 or
co-deletion of PDK1 has been shown to reverse most—but not
always all—phenotypes associated with PTEN deficiency in vivo
(Zhou et al., 2009; Sperow et al., 2012). Although this could
be due to subtle or specific requirements of PTEN’s lipid phos-
phatase activity depending on the cellular or developmental con-
text, it is also suggestive of, perhaps latent, PI3K-independent
functional outputs of PTENwhich are important for proper brain
development.
ASD-associated PTEN mutations
The study of the mutational spectrum of PTEN in ASD patients
has revealed at least 25 mutations to date, of which 16 are
amino-acid substitutions (Table 1) (Rodríguez-Escudero et al.,
2011; Klein et al., 2013; Hobert et al., 2014). More than half
of these mutations have also been identified in PHTS patients
or as somatic mutations in sporadic cancers. They are scat-
tered along the PTEN phosphatase and the C2 domain, and are
absent from theN-terminal and the C-terminal regions. The exact
effect of ASD-unique mutations on the properties of PTEN (i.e.,
residual phosphatase activity, altered membrane/protein interac-
tions, protein stability) is still poorly characterized. A number
of recent studies have suggested the possibility that ASD muta-
tions are less severe (i.e., mutant forms retain partial activity)
when compared to tumor-related mutations. The mostly stud-
ied ASD mutation in the context of its effect on PTEN activity
is PTEN H93R. This mutation also identified in CS, appears to
result in an 85% decrease in PTEN’s PIP3 phosphatase activ-
ity when measured against water-soluble PIP3 in vitro. Yet this
mutation increased PTEN association with PS-rich liposomes
in vitro, as well as increased membrane localization in vivo
(Redfern et al., 2010). Notably, when compared to wild-type
PTEN, PTEN H93R was unable to fully reduce PI3K-dependent
Akt phosphorylation in U87MG glioblastoma cells, indicating a
partial loss of activity in vivo (Redfern et al., 2010). Also, using
a heterologous yeast PI3K-activity reconstitution system, PTEN
H93R appeared to retain residual phosphatase activity when com-
pared to PHTS PTENmutants (Rodríguez-Escudero et al., 2011).
Thus, it would appear that complete loss of PTEN phosphatase
activity and/or PTEN stability is rather an infrequent event in
ASD cases (Zhou and Parada, 2012). However, in addition to
understanding the molecular effect of these ASD-unique muta-
tions, their exact effect on the modulation of morphology and
synaptic plasticity by PTEN awaits detailed analyses in neuronal
cells.
PTEN functions in dendritic spines
Given the dominant effects of PTEN depletion on neuronal cell
morphology and gross architecture of brain structures, it has been
important to delineate the exact PTEN requirements for spe-
cific synaptic, behavioral and neuroanatomical defects observed
in ASD-related PTEN mouse models. Importantly, a series of
recent studies have highlighted that PTEN deletion results in spe-
cific early-onset deficits in postsynaptic plasticity that may even
precede minor and gross anatomical changes. Depending on the
experimental approach, the developmental stage and the mode
of PTEN inactivation, loss of PTEN has been shown to result in
changes in synaptic function including both forms of synaptic
plasticity, long-term potentiation (LTP) and long-term depres-
sion (LTD) (Sperow et al., 2012; Takeuchi et al., 2013). Often,
these changes are observed in the absence of the hypertrophy
phenotypes that are characteristic of PTEN loss in postmitotic
neurons (i.e., increases in soma size and dendritic spine den-
sity and dendrite arborization) (Sperow et al., 2012), suggesting
that a primary role of PTEN is the regulation of synaptic func-
tion within the postsynaptic compartment. Thus, it is tempting
to speculate that there is a spine-specific PTEN pool, which
actively participates in the regulation of essential synaptic func-
tions locally.
It has been suggested that a continuous turnover of PIP3 at
the spine may support synaptic function, at least by maintaining
synaptic retention of AMPAR (α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor) under basal conditions (Arendt
et al., 2010). Furthermore, PI3K is activated upon LTP induc-
tion and it is also required for various forms of LTD (Kim et al.,
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2011a). PTEN is recruited to the PSD upon NMDAR activa-
tion, primarily via PDZ-dependent interactions with PSD-95
(Jurado et al., 2010). In this case, it has been proposed that PTEN
lipid phosphatase activity is able to drive depression of AMPAR-
mediated synaptic responses. This activity is specifically required
for NMDA receptor-dependent LTD (Jurado et al., 2010). Other
studies have suggested that the recruitment of PTEN into the
postsynaptic compartment may lead to modifications in pro-
teins implicated in synaptic function involving specifically the
protein phosphatase activity (Kreis et al., 2013). PTEN’s protein
phosphatase activity in neurons has been less well-characterized,
although increasing evidence suggests that it may be important
for regulating PTEN itself through auto-phosphorylation as well
as through other protein substrates. For example, overexpression
Table 1 | ASD-associated missense mutations.
Mutationa Macrocephalyb Cancerc Domain Activityd Notese
M1I +
P38H + Phosphatase
Y68N + + Phosphatase Y68D in PS
L70V + Phosphatase
H93R + + Phosphatase ++ CS
H118P + Phosphatase ++
H123Q + Phosphatase – H123D in CS,
P-loop
R130L + + Phosphatase Frequently
mutated in
cancer, P-loop
E157G + Phosphatase ++
R173H + + Phosphatase ++ CS,
phosphatase-
C2
interface
Y176C + Phosphatase +++ CS,
phosphatase-
C2
interface
F241S + + C2 – /+ CS
V255A + + C2
D252G + + C2 +++ Phosphatase-
C2
interface
N276S + C2 +++ Phosphatase-
C2
interface
D326N + C2
aData from Rodríguez-Escudero et al. (2011), Hobert et al. (2014), Klein et al.
(2013), Butler et al. (2005), Orrico et al. (2009), McBride et al. (2010), Varga et al.
(2009), Buxbaum et al. (2007). Truncations R130X, L139X, Y178X, R335X, and
R355X that presumably correspond to unstable/non-functional proteins are not
included in the table.
bAssociation with macrocephaly.
cOccurrence as somatic mutation in cancers (COSMIC database).
d Activity in the yeast system (Rodríguez-Escudero et al., 2011 – means no activ-
ity, +++ means full activity compared to wild type PTEN).
eAssociation with PHTS is indicated (PS, Proteus Syndrome; CS, Cowden
Syndrome), as well as the catalytic or structural significance.
of a protein phosphatase-deficient PTEN mutant, PTEN Y138L
(Tibarewal et al., 2012), in organotypic hippocampal slice cultures
does not phenocopy the effect of wild-type PTEN or PTENG129E
in reducing spine density (Zhang et al., 2012a). It has been sug-
gested that autodephosphorylation of PTEN in this context may
function in de-repressing the exposure of the C-terminal PDZ-
binding domain, thus allowing for PDZ domain-PTEN interac-
tions to take place (Zhang et al., 2012a). Alternatively, PTEN’s
protein phosphatase activity could be directed to other protein
substrates located in dendritic spines, such as Drebrin (Kreis et al.,
2013). Drebrin phosphorylation at S647 is under the control of
PTEN and it depends on direct complex formation of the two
proteins and synaptic activity (Kreis et al., 2013). In conclusion,
increasing the understanding of the molecular mechanisms that
controls PTEN movement into and out of the postsynaptic com-
partment, and those that direct PTEN lipid/protein phosphatase
activity might prove to be key to fully comprehend the impact of
PTEN mutations associated with neurological disorders.
PTEN AND AXON REGENERATION
PTEN’s role in regeneration became evident in a seminal study
that induced genetic deletion of PTEN, specifically in adult reti-
nal ganglion cells, which promoted regeneration of axonal fibers
after subjection to an optic nerve crush injury (Park et al., 2008).
Since then, research in finding ways to modify the expression
or the activity of PTEN have become of great interest in this
field. This might be particularly important for CNS neurons since
axonal regeneration, contrary to neurons of the PNS (periph-
eral nervous system), is extremely limited following injury, which
is due to both an inhibitory environment present at the side of
injury as well as a general diminished regenerative capacity of
affected neurons. Subsequent studies have shown that upon nerve
transection of PNS neurons, axon outgrowth is enhanced follow-
ing local inhibition of PTEN using the pharmacological PTEN
inhibitor BpV(pic) or following siRNA knockdown of PTEN
(Christie et al., 2010). PTEN loss using genetic deletion or shRNA
approaches has also been shown to increase corticospinal tract
sprouting, axon regeneration, and the enhanced formation of
synaptic structures in models for spinal cord injury using unilat-
eral pyramidotomy, dorsal hemisection, or complete spinal cord
crush (Liu et al., 2010; Zukor et al., 2013).
For successful regeneration after an injury to occur, the injured
axon tip must be remodeled to reform a growth cone. This trans-
formation involves major changes in the cytoskeleton, as well as
changes in membranous and cytoplasmic components that are
necessary for the synthesis of new molecules. Several downstream
effectors of PTEN have been shown to convey the information
of axon regrowth. The PI3K/Akt/mTORC1 pathway, in partic-
ular, which regulates protein synthesis, is one of the important
targets involved in axon regrowth. For example, pyramidotomy
induces the loss of mTORC1 activity, an event that can be pre-
vented by deletion of PTEN (Liu et al., 2010). Inhibition of
mTORC1 using rapamycin largely neutralized the regenerative
capacity of PTEN deleted neurons following axotomy (Park et al.,
2008), suggesting that the injured axon tip benefits from increased
mTORC1 activity in terms of the growth potential and regen-
erative growth. However, significant axon regeneration was still
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observed when inhibiting mTORC1, suggesting that other path-
ways may be involved (Park et al., 2008). Another study also
suggested mTORC1-independent pathways, where the increased
neurite outgrowth after PTEN deletion in the PNS, was not
affected by rapamycin (Christie et al., 2010). Interestingly, com-
bined activation of both the JAK/Stat and the PI3K/Akt/mTORC1
further increases the regenerative capacity of CNS neurons in the
optic nerve crush model (Sun et al., 2011), demonstrating the
significant interplay between different signaling pathways in pro-
moting regenerative growth as well as neuronal survival (Luo and
Park, 2012). Upstream of PTEN, signals mediated by inhibitors of
axon growth such as MAGs or Sema3A could be responsible for
preventing axon regeneration by activating PTEN. Indeed, dele-
tion of PTEN resulted in a significant, although partial rescue
of neurite outgrowth on MAG expressing CHO cells (Perdigoto
et al., 2011).
The prospect to increase the regenerative capacity of dam-
aged neurons by inhibiting PTEN has been of great interest for
therapeutic strategies. In amousemodel for spinal muscular atro-
phy (SMA), the knock down of PTEN rescued disease associated
defects in axon length, increased survival and restored growth
cone sizes (Ning et al., 2010). Similarly, inhibition of PTEN using
BpV(pic) has been shown to have a beneficial effect on spinal cord
injuries, leading to increases in the number of motoneurons at
the injury epicenter and improving forelimb articulation (Walker
et al., 2012). Inhibition of PTEN may also be a promising target
in amyotrophic lateral sclerosis (ALS), a well-studied degenerative
motor neuron disease that that can be linked to inactivatingmuta-
tions of the Cu/Zn superoxide dismutase SOD1. Usingmicroarray
analysis of SOD1 deficient ALS spinal cordmotor neurons, several
components of the PI3K signaling pathway were identified to be
dysregulated, which included PTEN (Kirby et al., 2011).
Collectively, these studies suggest that, at physiological set-
tings, PTEN functions in restricting regenerative growth in the
PNS and CNS neurons, and this is in agreement with PTEN’s role
in inhibiting the growth-promoting PI3K/Akt/mTORC1 path-
way. Furthermore, it appears that deletion or inhibition of PTEN
offers advanced neuroprotection by increasing neuronal survival.
One of the key questions will entail the analyses of the minimal
pool of PTEN that—once it is lost—induces regenerative growth
response. Thus, unraveling the specific functions of PTEN in the
different subcellular compartments of neurons should bring new
insights into the mechanisms necessary for the establishment of a
robust and sustained regeneration.
PTEN AND NEURODEGENERATIVE CONDITIONS
PTEN AND ALZHEIMER’S DISEASE
AD involves the degeneration of neurons and the accumula-
tion of pathological highly phosphorylated Tau protein species,
which eventually generate neurofibrillary tangles. The driving
force for AD, however, involves the overproduction of the amy-
loid β-peptides that form the extracellular deposits found in the
brains of patients with AD, the amyloid plaques. It was initially
shown that stimulation of the PI3K/Akt signaling pathway in vitro
through insulin-like growth factor may protect Aβ induced neu-
rotoxicity (Doré et al., 1997; Wei et al., 2002). This was in line
with the fact that GSK-3, which operates downstream of the
PI3K signaling pathway, had been identified as a potential kinase
responsible for causing hyper-phosphorylation of Tau (Hanger
et al., 1992). Later, the function of PI3K in neuronal survival
and AD showed the requirement of a more defined coordination
of the different components of the pathway. Contrary to initial
expectations, an overactivation of PI3K signaling was reported
in postmortem brain tissue in both immunohistochemistry and
immunobiochemistry with an increase in Akt activation, a loss
of neuronal cytosolic Akt and a loss and modified localization of
PTEN in the temporal cortex and hippocampus of AD patients
(Griffin et al., 2005). Interestingly, a loss of nuclear PTEN was
observed in neurons of the CA1, subiculum, and entorhinal cor-
tex, as well as in the temporal cortex of AD cases (Griffin et al.,
2005). In agreement with this, another study showed that PTEN
re-distributed from the nucleus to the cytoplasm in regions such
as the hippocampus and the entorhinal cortex of AD tissue and
accumulated in intracellular neurofibrillary tangles (Sonoda et al.,
2010). It has been suggested that the overactivation of the PI3K
signaling pathway and the observed decreases in PTEN protein
levels originate from a pro-survival response aimed at compen-
sating for the disease. Decreased PTEN protein abundances may
also impact on the phosphorylation state of Tau. Indeed, the lipid
phosphatase activity of PTEN may affect Tau phosphorylation as
in vitro studies have shown that PTEN can affect the formation of
Tau aggregates in a GSK3-independent manner (Kerr et al., 2006;
Zhang et al., 2006). The exact function of PTEN in Alzheimer dis-
ease remains, however, poorly understood, due to the complexity
of the disease and the existence of numerous compensatory feed-
back loops within the PI3K signaling pathway. Decisive proof of
whether the observed loss of PTEN in the nucleus in AD tis-
sue leads to an apoptotic or a prosurvival signal remains elusive.
Similarly, detailed information on the function of PTEN and/or
its modified localization in other subcellular compartments such
as the ER, the mitochondria or the MAMs are still not avail-
able. Nevertheless, PTEN may play a key role in the regulation
of calcium signaling and apoptotic responses that are both per-
turbed in AD and are associated with these compartments. For
instance, as mentioned in the previous section, PTEN recruited
at the MAM-ER membranes (Bononi et al., 2013) could have an
effect on modification in the calcium transfer from the ER to
the mitochondria that has been observed following Aβ treatment
(Hedskog et al., 2013). A similar contribution of PTEN could
potentially relate to its interaction with the pro-apoptotic protein
Bax at the mitochondria and regulation of apoptotic signaling
pathways (Zu et al., 2011). Again, these ideas, though plausible,
have not yet been tested in the context of AD research.
PTEN AND PARKINSON’S DISEASE
Parkinson’s disease (PD) is the second most prevalent neurode-
generative disorder after Alzheimer’s. It is characterized by pro-
gressive loss of dopaminergic neurons in the substantia nigra pars
compacta. Earlier studies provided links for PTEN’s involvement
in the pathogenesis of PD by virtue of its indirect and direct
interactions, respectively, with two prominent PD-associated
genes, PINK1 and DJ-1. However, more recent studies utilizing
primarily neuron subtype-specific PTEN cKO mice have sug-
gested diverse roles for PTEN and the Akt/mTOR pathway in
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dopaminergic neurons. It has been shown, for instance, that inhi-
bition of PTEN in dopaminergic cell lines significantly inhibits
the neuronal death caused by 1-methyl-4-phenylpyridinium
(MPP+), an established in vitro model of PD toxicity (Zhu et al.,
2007). Dopaminergic neuron-specific deletion of PTEN recapitu-
lated the hypertrophy phenotype observed in other cKO mouse
models (Diaz-Ruiz et al., 2009). In addition, PTEN inactiva-
tion protected dopaminergic neurons and significantly enhanced
dopamine-dependent behavioral functions in cKO mice after a
progressive 6-hydroxydopamine (6OHDA) lesion, where applica-
tion of this neurotoxin into the striatum results in progressive loss
of neurons in the ventral mesencephalon (Diaz-Ruiz et al., 2009).
Subsequent studies in adult mice using an inducible Cre system
showed that specific ablation of PTEN in adult dopaminergic
neurons is neuroprotective in genetic and neurotoxin-induced
mouse models of PD (Domanskyi et al., 2011). In this case, PTEN
deletion attenuated the loss of tyrosine hydroxylase-positive cells
after 6OHDA treatment. Also, specific ablation of an essential
factor controlling ribosomal RNA transcription, TifIa, in adult
mouse dopaminergic neurons represses mTOR signaling and
leads to progressive neurodegeneration and PD-like phenotype.
Here, PTEN deletion rescued locomotor impairments caused by
absence of Tifla (Domanskyi et al., 2011). These more recent
studies are in accordance with an earlier report showing that
overactivation of PI3K signaling, by adenoviral transduction of
a membrane-localized Akt1 form into substantia nigra neurons,
offers protection against 6OHDA (Ries et al., 2006). Another
example of the general applicability and beneficial effects of
PTEN deletion in PD mouse models is the enhanced survival,
function and integration of grafted PTEN−/− dopaminergic neu-
rons within the striatum of MitoPark mice, a model that shows
progressive parkinsonism after specific inactivation of the mito-
chondrial respiratory chain in midbrain dopaminergic neurons
(Zhang et al., 2012b).
A specific requirement for PTEN in the regulation of axon ter-
minal morphology of dopaminergic neurons has been uncovered
in neurons deficient in an essential macroautophagy component,
Atg7 (Inoue et al., 2013). In these mice, midbrain dopaminer-
gic neurons exhibit strikingly enlarged axon terminals and also
late-onset degeneration in vivo. Interestingly, although PTEN-
deficient dopaminergic neurons show no alteration at the axon
terminal, concomitant deletion of PTEN and Atg7 results in a
exacerbation of the axon terminal size seen in Atg7 deficient
neurons in the absence of any degeneration phenotype (Inoue
et al., 2013). These results suggest that macroautophagic activ-
ity, at least in dopaminergic neurons, may limit the impact
of PTEN/PI3K/mTOR pathway on axon terminal morphology
(Inoue et al., 2013).
In conclusion, an overall protective effect against neuronal
death has been demonstrated when PTEN is deleted or inac-
tivated in dopaminergic neurons, which is likely to reflect a
generalized response due to activation of the PI3K/Akt/mTOR
signaling pathway.
CONCLUDING REMARKS
Numerous specific modes of PTEN functions have been identi-
fied that are restricted to diverse subcellular compartments and
involved in mediating a plethora of cellular responses. It has
become increasingly clear that PTEN functions are not exclusively
restricted to targeting phosphoinositides in membranous com-
partments; instead, PTEN specific cellular responses also involve
its protein phosphatase activity or, no phosphatase activity at all.
On one hand, PTEN inhibition has become a potentially attrac-
tive therapeutic intervention in certain settings. Yet, on the other
hand, PTEN activation could be beneficial in other conditions.
So far, chemical compounds that can act as PTEN inhibitors have
been shown to substantially corroborate findings from studies
utilizing deletion and silencing approaches. In principal, ratio-
nal design of chemical compounds or peptides to shift, or prevent
PTEN’s localization to a specific subcellular compartment, to alter
binding to a prominent protein partner, or to impose specific
structural conformations on PTEN are plausible. Furthermore,
the implications of using PTEN itself as an exogenous factor are
only now beginning to be appreciated. In this review, we have
attempted to detail some of the roles of PTEN that are, or may
turn out to be involved, in mediating cellular responses in the
developing, the mature, as well as the diseased neuron. No doubt,
the interplay between the mechanisms that coordinate subcellu-
lar targeting in the context of controlling enzymatic activity will
require detailed attention and have to be further explored.
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